← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Tempus AI, Inc. (TEM) 10-Year Financial Performance & Capital Metrics

TEM • • Industrial / General
HealthcareHealthcare ITGenomics & Precision MedicineGenomic Testing & Analysis
AboutTempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.Show more
  • Revenue $693M +30.4%
  • EBITDA -$654M -301.7%
  • Net Income -$706M -229.6%
  • EPS (Diluted) -4.60 -166.9%
  • Gross Margin 54.96% +2.1%
  • EBITDA Margin -94.29% -208.1%
  • Operating Margin -99.67% -170.3%
  • Net Margin -101.79% -152.8%
  • ROE -1252.79%
  • ROIC -282.49%
  • Debt/Equity 8.31
  • Interest Coverage -12.88 -207.9%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Strong 5Y sales CAGR of 62.0%

✗Weaknesses

  • ✗High debt to equity ratio of 8.3x
  • ✗Negative free cash flow
  • ✗Low quality earnings: Net income not backed by cash flow
  • ✗Trading more than 30% below 52-week high
  • ✗Expensive at 198.3x book value

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y62.05%
3Y39.06%
TTM72.58%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM72.57%

EPS CAGR

10Y-
5Y-
3Y-
TTM76.81%

ROCE

10Y Avg-62.58%
5Y Avg-67.76%
3Y Avg-84.5%
Latest-143.01%

Peer Comparison

Genomic Testing & Analysis
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
SOPHSOPHiA GENETICS S.A.350.09M5.16-5.434.49%-102.29%-123.55%0.31
TEMTempus AI, Inc.11.91B68.92-14.9730.38%-18.45%-40.15%8.31
WGSGeneDx Holdings Corp.3.16B109.28-56.3350.79%0.52%0.71%0.47

Profit & Loss

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+62.06M188M257.85M320.67M531.82M693.4M
Revenue Growth %-2.03%0.37%0.24%0.66%0.3%
Cost of Goods Sold+46.02M159.29M174.21M190.48M245.65M312.29M
COGS % of Revenue0.74%0.85%0.68%0.59%0.46%0.45%
Gross Profit+16.04M28.71M83.64M130.19M286.18M381.11M
Gross Margin %0.26%0.15%0.32%0.41%0.54%0.55%
Gross Profit Growth %-0.79%1.91%0.56%1.2%0.33%
Operating Expenses+135.82M222.17M327.36M395.63M482.26M1.07B
OpEx % of Revenue2.19%1.18%1.27%1.23%0.91%1.55%
Selling, General & Admin78.96M130.89M199M233.38M296.76M755.35M
SG&A % of Revenue1.27%0.7%0.77%0.73%0.56%1.09%
Research & Development56.86M91.28M128.35M162.25M185.5M316.84M
R&D % of Revenue0.92%0.49%0.5%0.51%0.35%0.46%
Other Operating Expenses000000
Operating Income+-119.78M-193.45M-243.71M-265.44M-196.08M-691.08M
Operating Margin %-1.93%-1.03%-0.95%-0.83%-0.37%-1%
Operating Income Growth %--0.62%-0.26%-0.09%0.26%-2.52%
EBITDA+-104.76M-170.4M-219.83M-235.03M-162.75M-653.84M
EBITDA Margin %-1.69%-0.91%-0.85%-0.73%-0.31%-0.94%
EBITDA Growth %--0.63%-0.29%-0.07%0.31%-3.02%
D&A (Non-Cash Add-back)15.02M23.05M23.88M30.41M33.33M37.24M
EBIT-114.92M-192.43M-243.4M-267.26M-166.66M-647.66M
Net Interest Income+4.83M-17.43M-14.56M-18.86M-39.27M-42.57M
Interest Income4.86M1.5M623K3.03M7.6M11.08M
Interest Expense28K18.93M15.18M21.89M46.87M53.65M
Other Income/Expense4.83M-16.4M-15.48M-24.3M-17.75M-14.46M
Pretax Income+-114.95M-209.85M-259.19M-289.75M-213.83M-705.54M
Pretax Margin %-1.85%-1.12%-1.01%-0.9%-0.4%-1.02%
Income Tax+00066K288K266K
Effective Tax Rate %1%1%1%1%1%1%
Net Income+-114.95M-209.85M-259.19M-289.81M-214.12M-705.81M
Net Margin %-1.85%-1.12%-1.01%-0.9%-0.4%-1.02%
Net Income Growth %--0.83%-0.24%-0.12%0.26%-2.3%
Net Income (Continuing)-114.95M-209.85M-259.19M-289.81M-214.12M-705.81M
Discontinued Operations000000
Minority Interest000000
EPS (Diluted)+-0.92-1.49-1.75-1.97-1.73-4.60
EPS Growth %--0.62%-0.17%-0.12%0.12%-1.67%
EPS (Basic)-0.92-1.49-1.75-1.97-1.73-4.60
Diluted Shares Outstanding160.71M169.88M169.88M169.88M154.17M162.12M
Basic Shares Outstanding160.71M169.88M169.88M169.88M154.17M162.12M
Dividend Payout Ratio------

Balance Sheet

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+276.23M649.73M403.99M438.63M350.33M667.6M
Cash & Short-Term Investments227.6M513.44M277.69M302.94M197.57M448.26M
Cash Only227.6M513.44M277.69M302.94M165.77M340.95M
Short-Term Investments000031.81M107.31M
Accounts Receivable31.89M87.26M82.24M88.68M94.46M154.82M
Days Sales Outstanding187.56169.41116.42100.9464.8381.5
Inventory8.28M37.56M22.91M22.28M28.84M38.39M
Days Inventory Outstanding65.6786.064842.742.8644.87
Other Current Assets8.47M11.48M21.15M24.73M29.45M26.14M
Total Non-Current Assets+93.94M102.19M127.37M192.74M213.72M258.51M
Property, Plant & Equipment36.06M38.44M35.4M67.79M82.21M72.82M
Fixed Asset Turnover1.72x4.89x7.29x4.73x6.47x9.52x
Goodwill15.99M15.99M15.98M53.1M73.35M73.34M
Intangible Assets41.33M44.46M37.29M37.28M21.92M11.72M
Long-Term Investments0000091.45M
Other Non-Current Assets558K3.3M38.7M34.57M36.24M9.19M
Total Assets+370.17M751.92M531.35M631.36M564.05M926.12M
Asset Turnover0.17x0.25x0.49x0.51x0.94x0.75x
Asset Growth %-1.03%-0.29%0.19%-0.11%0.64%
Total Current Liabilities+43.73M101.38M114.81M174.24M232.63M291.07M
Accounts Payable13.41M53.57M33.75M45.99M54.42M53.8M
Days Payables Outstanding106.41122.7570.7288.1280.8662.89
Short-Term Debt000000
Deferred Revenue (Current)1000K1000K1000K1000K1000K1000K
Other Current Liabilities5.72M14.01M22.33M24.73M30.16M31.73M
Current Ratio6.32x6.41x3.52x2.52x1.51x2.29x
Quick Ratio6.13x6.04x3.32x2.39x1.38x2.16x
Cash Conversion Cycle146.82132.7193.755.5226.8363.48
Total Non-Current Liabilities+580.85M1.16B1.22B1.59B1.71B578.71M
Long-Term Debt0250M238.24M389.55M449.67M435.44M
Capital Lease Obligations1.44M724K291K37.13M32.04M26.2M
Deferred Tax Liabilities000000
Other Non-Current Liabilities579.41M912.8M985.51M1.12B1.22B86.43M
Total Liabilities624.59M1.26B1.34B1.76B1.95B869.78M
Total Debt+2.59M251.45M238.95M433.03M488.14M468.09M
Net Debt-225.01M-261.99M-38.74M130.09M322.38M127.14M
Debt / Equity-----8.31x
Debt / EBITDA------
Net Debt / EBITDA------
Interest Coverage-4277.89x-10.22x-16.05x-12.12x-4.18x-12.88x
Total Equity+-254.41M-512.98M-807.49M-1.13B-1.38B56.34M
Equity Growth %--1.02%-0.57%-0.4%-0.22%1.04%
Book Value per Share-1.58-3.02-4.75-6.65-8.960.35
Total Shareholders' Equity-254.41M-512.98M-807.49M-1.13B-1.38B56.34M
Common Stock6K6K6K6K6K17K
Retained Earnings-257.85M-512.99M-807.49M-1.14B-1.4B-2.15B
Treasury Stock0000-3.6M-3.6M
Accumulated OCI1K-1K-11K18K5K94K
Minority Interest000000

Cash Flow

Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-117.11M-206.56M-211.98M-168.2M-214.34M-189.04M
Operating CF Margin %-1.89%-1.1%-0.82%-0.52%-0.4%-0.27%
Operating CF Growth %--0.76%-0.03%0.21%-0.27%0.12%
Net Income-114.95M-209.85M-259.19M-289.81M-214.12M-705.81M
Depreciation & Amortization15.02M23.05M23.88M30.41M33.33M37.24M
Stock-Based Compensation529K399K559K00534.14M
Deferred Taxes000000
Other Non-Cash Items3.65M15.29M8.22M19.38M4.28M-16.82M
Working Capital Changes-21.36M-35.45M14.55M71.82M-37.84M-37.8M
Change in Receivables-13.37M-55.84M4.75M-8.2M-7.35M-61.04M
Change in Inventory-3.47M-29.28M14.65M-1.31M-6.56M-9.54M
Change in Payables038.13M-30.47M-7.92M-23.36M-23.85M
Cash from Investing+-43.03M-13.42M-21.72M-57.94M-40.31M-130.39M
Capital Expenditures-17.04M-13.42M-11.77M-18.38M-34.61M-22.12M
CapEx % of Revenue0.27%0.07%0.05%0.06%0.07%0.03%
Acquisitions------
Investments------
Other Investing00-4M000
Cash from Financing+196.69M506.11M-2.04M251.39M117.55M494.33M
Debt Issued (Net)------
Equity Issued (Net)------
Dividends Paid-5.29M-5.63M-5.63M-5.63M-5.63M-5.63M
Share Repurchases------
Other Financing00-4.51M-5.43M-698K-79.5M
Net Change in Cash------
Free Cash Flow+-134.15M-219.98M-223.75M-186.58M-248.95M-211.17M
FCF Margin %-2.16%-1.17%-0.87%-0.58%-0.47%-0.3%
FCF Growth %--0.64%-0.02%0.17%-0.33%0.15%
FCF per Share-0.83-1.29-1.32-1.10-1.61-1.30
FCF Conversion (FCF/Net Income)1.02x0.98x0.82x0.58x1.00x0.27x
Interest Paid02.05M80K4.66M16.91M28.05M
Taxes Paid08K3K6K161K206K

Key Ratios

Metric201920202021202220232024
Return on Equity (ROE)------1252.79%
Return on Invested Capital (ROIC)------282.49%
Gross Margin25.85%15.27%32.44%40.6%53.81%54.96%
Net Margin-185.23%-111.62%-100.52%-90.38%-40.26%-101.79%
Debt / Equity-----8.31x
Interest Coverage-4277.89x-10.22x-16.05x-12.12x-4.18x-12.88x
FCF Conversion1.02x0.98x0.82x0.58x1.00x0.27x
Revenue Growth-202.95%37.15%24.36%65.85%30.38%

Frequently Asked Questions

Growth & Financials

Tempus AI, Inc. (TEM) reported $1.11B in revenue for fiscal year 2024. This represents a 1681% increase from $62.1M in 2019.

Tempus AI, Inc. (TEM) grew revenue by 30.4% over the past year. This is strong growth.

Tempus AI, Inc. (TEM) reported a net loss of $203.9M for fiscal year 2024.

Dividend & Returns

Tempus AI, Inc. (TEM) does not currently pay a meaningful dividend. The company may be reinvesting profits for growth.

Tempus AI, Inc. (TEM) has a return on equity (ROE) of -1252.8%. Negative ROE indicates the company is unprofitable.

Tempus AI, Inc. (TEM) had negative free cash flow of $248.1M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.